- Home
- DYN
as 07-26-2024 4:00pm EST
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 3.1B | IPO Year: | 2020 |
| Target Price: | $42.56 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.40 - $45.46 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Jun 12 '24 | Sell | $33.17 | 26,036 | $863,614.12 | 162,756 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Jun 12 '24 | Sell | $33.70 | 13,964 | $470,586.80 | 148,792 | SEC Form 4 |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Jun 11 '24 | Sell | $31.34 | 2,136 | $66,942.24 | 147,511 | SEC Form 4 |
| Farwell Wildon | DYN | Chief Medical Officer | Jun 11 '24 | Sell | $31.27 | 1,628 | $50,907.56 | 146,551 | SEC Form 4 |
| Farwell Wildon | DYN | Chief Medical Officer | Jun 11 '24 | Sell | $31.27 | 1,008 | $31,520.16 | 145,543 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | Jun 11 '24 | Sell | $31.34 | 1,823 | $57,132.82 | 134,811 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Jun 10 '24 | Sell | $30.24 | 80,000 | $2,419,200.00 | 154,062 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Jun 10 '24 | Sell | $31.23 | 2,357 | $73,609.11 | 151,705 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Jun 10 '24 | Sell | $31.23 | 2,913 | $90,972.99 | 148,792 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Jun 10 '24 | Sell | $30.23 | 1,590 | $48,065.70 | 115,105 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Jun 10 '24 | Sell | $31.34 | 1,331 | $41,713.54 | 113,774 | SEC Form 4 |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | May 20 '24 | Sell | $32.49 | 17,134 | $556,683.66 | 162,939 | SEC Form 4 |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | May 20 '24 | Sell | $33.51 | 12,147 | $407,045.97 | 150,792 | SEC Form 4 |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | May 20 '24 | Sell | $34.08 | 1,145 | $39,021.60 | 149,647 | SEC Form 4 |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | May 16 '24 | Sell | $28.59 | 483 | $13,808.97 | 149,647 | SEC Form 4 |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | May 16 '24 | Sell | $28.20 | 2,222 | $62,660.40 | 150,130 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | May 16 '24 | Sell | $28.20 | 2,249 | $63,421.80 | 154,551 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | May 16 '24 | Sell | $28.59 | 489 | $13,980.51 | 154,062 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | May 16 '24 | Sell | $28.20 | 2,126 | $59,953.20 | 117,157 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | May 16 '24 | Sell | $28.59 | 462 | $13,208.58 | 116,695 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | May 16 '24 | Sell | $28.20 | 2,279 | $64,267.80 | 137,129 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | May 16 '24 | Sell | $28.59 | 495 | $14,152.05 | 136,634 | SEC Form 4 |
| Farwell Wildon | DYN | Chief Medical Officer | May 16 '24 | Sell | $28.20 | 1,956 | $55,159.20 | 148,604 | SEC Form 4 |
| Farwell Wildon | DYN | Chief Medical Officer | May 16 '24 | Sell | $28.59 | 425 | $12,150.75 | 148,179 | SEC Form 4 |
| Farwell Wildon | DYN | Chief Medical Officer | Mar 11 '24 | Sell | $25.70 | 1,585 | $40,734.50 | 151,590 | SEC Form 4 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
Zacks
14 days ago
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
MT Newswires
17 days ago
JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating
MT Newswires
a month ago
Dyne Therapeutics Insider Sold Shares Worth $1,401,902, According to a Recent SEC Filing
GlobeNewswire
a month ago
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
MT Newswires
a month ago
Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing
GlobeNewswire
a month ago
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
MT Newswires
a month ago
Dyne Therapeutics Insider Sold Shares Worth $2,583,782, According to a Recent SEC Filing
Compare DYN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.